arrow
M

Maria Bieniaszewska

Medical University of Gdańsk
H指数:14
被引数:1,555

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

miR-302d-3p expression and genotype are associated with CMV replication after allogeneic haematopoietic stem cell transplantation

miR-302d-3p的表达和基因型与异基因造血干细胞移植后的CMV复制相关

2025-10-080
OAAI
ILT-2 and ILT-4 expression and donor genotype as factors associated with HSCT outcome

ILT-2和ILT-4的表达以及供者基因型作为与HSCT结局相关的因素

2025-10-020
PRE
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera

治疗对青少年和年轻成人真性红细胞增多症和原发性血小板增多症的影响

LEUKEMIA
IF13.4
2025-03-120
OA
Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity

NK细胞受体遗传变异对异基因造血干细胞移植结局及体外NK细胞毒性的影响

2024-11-060
OAAI
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

ROP-ET:一项前瞻性III期试验,旨在研究罗普司坦alfa-2b在治疗治疗选择有限的真性红细胞增多症患者中的有效性和安全性

BLOOD
IF23.1
2024-11-050
OA
Soluble MICA concentrations and genetic variability of MICA and its NKG2D receptor as factors affecting Graft-versus-Host Disease development after allogeneic haematopoietic stem cell transplantation

可溶性MICA浓度和MICA及其NKG2D受体的遗传变异性是异基因造血干细胞移植后移植物抗宿主病发展的影响因素

2024-11-010
OAAI
Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort

多种群队列中胸腺生成的供体遗传决定因素,rs2204985和干细胞移植结果

2024-05-010
OAAI
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
2024-03-044
OAAI
Dual-Activity Fluoroquinolone-Transportan 10 Conjugates Offer Alternative Leukemia Therapy during Hematopoietic Cell Transplantation
2024-01-013
PRE
Significance of HLA-E and its two NKG2 receptors in development of complications after allogeneic transplantation of hematopoietic stem cells

Hla-e及其两种NKG2受体在异基因造血干细胞移植后并发症发生中的意义

2023-10-132
OAAI
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
2022-09-0620
OAAI
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
2022-06-0832
OA
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
2020-01-0198
PREAI
HLA-inferred extended haplotype disparity level is more relevant than the level of HLA mismatch alone for the patients survival and GvHD in T cell-replate hematopoietic stem cell transplantation from unrelated donor
2018-06-0111
PREAI